Suppr超能文献

2019 - 2020年中国北京通州区疱疹性咽峡炎患儿的分子流行病学研究

Molecular Epidemiology of Herpangina Children in Tongzhou District, Beijing, China, During 2019-2020.

作者信息

Xie Ming-Zhu, Chen Lin-Yi, Yang Yan-Na, Cui Yan, Zhang Si-Hui, Zhao Tian-Shuo, Zhang Wan-Xue, Du Juan, Cui Fu-Qiang, Lu Qing-Bin

机构信息

Department of Laboratorial Science and Technology and Vaccine Research Center, School of Public Health, Peking University, Beijing, China.

Institute for Infectious Diseases and Endemic Diseases Prevention and Control, Beijing Tongzhou Center for Disease Control and Prevention, Beijing, China.

出版信息

Front Med (Lausanne). 2022 Apr 25;9:822796. doi: 10.3389/fmed.2022.822796. eCollection 2022.

Abstract

BACKGROUND

The changing pattern of pathogen spectrum causing herpangina in the time of coronavirus disease 2019 (COVID-19) pandemic was unknown. The purpose of this study was to investigate the changes on the molecular epidemiology of herpangina children during 2019-2020 in Tongzhou district, Beijing, China.

METHOD

From January 2019 to December 2020, children diagnosed with herpangina were recruited by the staff from Tongzhou Center for Disease Control and Prevention (CDC) in Beijing. Viral RNA extraction from pharyngeal swabs was used for enterovirus (EV) detection and the complete VP1 gene was sequenced. The phylogenetic analysis was performed based on all VP1 sequences for EV genotypes.

RESULT

A total of 1,331 herpangina children were identified during 2019-2020 with 1,121 in 2019 and 210 in 2020, respectively. The predominant epidemic peak of herpangina children was in summer and autumn of 2019, but not observed in 2020. Compared to the number of herpangina children reported in 2019, it decreased sharply in 2020. Among 129 samples tested in 2019, 61 (47.3%) children were detected with EV, while 22.5% (20/89) were positive in 2020. The positive rate for EV increased since June 2019, peaked at August 2019, and decreased continuously until February 2020. No cases were observed from February to July in 2020, and the positive rate of EV rebounded to previous level since August 2020. Four genotypes, including coxsackievirus A6 (CV-A6, 9.3%), CV-A4 (7.8%), CV-A10 (2.3%) and CV-A16 (10.1%), were identified in 2019, and only three genotypes, including CV-A6 (9.0%), CV-A10 (6.7%) and CV-A16 (1.1%), were identified in 2020. The phylogenetic analysis showed that all CV-A6 strains from Tongzhou located in Group C, and the predominant strains mainly located in C2-C4 subgroups during 2016-2018 and changed into C1 subgroup during 2018-2020. CV-A16 strains mainly located in Group B, which consisting of strains widely distributed around the world.

CONCLUSIONS

The predominant genotypes gradually shifted from CV-A16, CV-A4 and CV-A6 in 2019 to CV-A6 in 2020 under COVID-19 pandemic. Genotype-based surveillance will provide robust evidence and facilitate the development of public health measures.

摘要

背景

2019年冠状病毒病(COVID-19)大流行期间,引起疱疹性咽峡炎的病原体谱变化情况尚不清楚。本研究旨在调查2019 - 2020年中国北京市通州区疱疹性咽峡炎患儿的分子流行病学变化。

方法

2019年1月至2020年12月,北京市通州区疾病预防控制中心(CDC)工作人员招募诊断为疱疹性咽峡炎的患儿。采用从咽拭子中提取病毒RNA的方法进行肠道病毒(EV)检测,并对完整的VP1基因进行测序。基于所有EV基因型的VP1序列进行系统发育分析。

结果

2019 - 2020年共鉴定出1331例疱疹性咽峡炎患儿,其中2019年1121例,2020年210例。疱疹性咽峡炎患儿的主要流行高峰出现在2019年夏秋季节,2020年未观察到。与2019年报告的疱疹性咽峡炎患儿数量相比,2020年急剧下降。2019年检测的129份样本中,61例(47.3%)患儿检测出EV,而2020年阳性率为22.5%(20/89)。EV阳性率自2019年6月开始上升,2019年8月达到峰值,随后持续下降至2020年2月。2020年2月至7月未观察到病例,自2020年8月起EV阳性率回升至之前水平。2019年鉴定出4种基因型,包括柯萨奇病毒A6(CV - A6,9.3%)、CV - A4(7.8%)、CV - A10(2.3%)和CV - A16(10.1%),2020年仅鉴定出3种基因型,包括CV - A6(9.0%)、CV - A10(6.7%)和CV - A16(1.1%)。系统发育分析表明,通州所有CV - A6毒株均位于C组,2016 - 2018年主要毒株位于C2 - C4亚组,2018 - 2020年转变为C1亚组。CV - A16毒株主要位于B组,该组毒株在全球广泛分布。

结论

在COVID - 19大流行期间,优势基因型逐渐从2019年的CV - A16、CV - A4和CV - A6转变为2020年的CV - A6。基于基因型的监测将提供有力证据并促进公共卫生措施的制定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f28/9082675/ac0e8b048bf1/fmed-09-822796-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验